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In-vitro and in-vivo antagonistic action of an anti-amylin
Spiegelmer
Abstract
The anorectic and dipsogenic effects of the pancreatic hormone amylin are mediated by the area
postrema and the subfornical organ. We tested the effectiveness of a new amylin antagonist, a so-called
RNA Spiegelmer, by electrophysiological in-vitro recordings from the rat subfornical organ and by
immunohistological c-Fos studies in the area postrema. Amylin's excitatory effect on subfornical organ
neurons was blocked by the anti-amylin Spiegelmer. Peripheral administration 5 h prior to amylin also
suppressed the amylin-induced activation (c-Fos expression) in the area postrema. The biostable
anti-amylin Spiegelmer may be therapeutically beneficial in conditions associated with high plasma
amylin levels, such as cancer anorexia occurring during certain pancreatic tumors.
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The anorectic and dipsogenic e¡ects of the pancreatic hormone
amylin are mediated by the area postrema and the subfornical
organ.We tested the e¡ectiveness of a new amylin antagonist, a
so-called RNA Spiegelmer, by electrophysiological in-vitro record-
ings from the rat subfornical organ and by immunohistological
c-Fos studies in the area postrema. Amylin’s excitatory e¡ect
on subfornical organ neurons was blocked by the anti-amylin
Spiegelmer. Peripheral administration 5h prior to amylin also sup-
pressed the amylin-induced activation (c-Fos expression) in the
area postrema.The biostable anti-amylin Spiegelmer may be ther-
apeutically bene¢cial in conditions associated with high plasma
amylin levels, such as cancer anorexia occurring during certain
pancreatic tumors. NeuroReport 18:1855^1859 c 2007 Wolters
Kluwer Health | LippincottWilliams &Wilkins.
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Introduction
Amylin is a 37-amino acid peptide, cosecreted with insulin
from pancreatic -cells in response to food intake [1].
Exogenous amylin potently reduces food intake [2,3], gastric
emptying and glucagon secretion [4,5]. Peripheral amylin’s
anorectic action seems to be mediated by the area postrema
[6,7], a circumventricular organ lacking a functional blood–
brain barrier [8]. In addition to its anorectic effect, amylin
may also contribute to prandial drinking most likely via an
action on angiotensin-II-sensitive neurons of the subfornical
organ [9]. The subfornical organ also belongs to the
circumventricular organs and, similar to the area postrema,
expresses a high density of amylin binding sites [10–12]. As
a member of the calcitonin family, amylin binds to calcitonin
receptors that exhibit an affinity for amylin when coex-
pressed with receptor activity modifying protein 1 or 3
[13,14].
In previous electrophysiological and immunohistological
studies, we characterized the effects of amylin on neuronal
activity in the area postrema [15,16] and the subfornical
organ [9,17]. In both structures, amylin induces dose-
dependent excitatory effects that are blocked by the
peptidergic amylin antagonist AC187. AC187, a truncated
analog of salmon calcitonin [18], reduces the excitatory
effect of amylin on area postrema and subfornical organ
neurons [9,16], the amylin-induced c-Fos expression in the
area postrema [15] and attenuates peripheral amylin’s
anorectic effect when infused directly into the area postrema
[7]. Recently, a new class of hormone antagonists has been
developed, the so-called Spiegelmers (German: Spie-
gel¼mirror). Spiegelmers are mirror image L-oligonucleo-
tides with high affinity toward a given target molecule,
leading to a blockade of its biological activity [see Ref. [19]
for review]. Owing to their L-ribose containing sugar–
phosphate backbone, Spiegelmers are highly resistant to
nuclease degradation and remain stable for more than 60 h
in biological fluids such as human plasma [19]. In addition
to their usefulness as experimental tools, they may also be
used as therapeutic agents. It has already been demon-
strated that the anti-ghrelin Spiegelmer NOX-B11 when
infused into the tail vein, suppresses ghrelin-induced food
intake and c-Fos induction in the arcuate nucleus in rats
[20]. Together with the observation that chronic NOX-B11
administration lowers body weight [20,21], it may be
beneficial for the treatment of obesity.
The aim of this study was to provide functional in-vitro
and in-vivo evidence that a newly developed anti-amylin
Spiegelmer antagonizes the effects of amylin on area
postrema and subfornical organ neurons. We used two
different approaches: (i) in electrophysiological single cell
recordings obtained from slice preparations, we investi-
gated the ability of the anti-amylin Spiegelmer to block the
excitatory action of amylin on subfornical organ neurons
in-vitro; (ii) in immunohistological studies we determined
whether the anti-amylin Spiegelmer blocks the amylin-
induced c-Fos expression in the area postrema under in-vivo
conditions.
Methods
The anti-amylin Spiegelmer used in this study is a 42
nucleotide L-RNA with the sequence 50-GGACUGAUG
GCGCGGUCCUAUUACGCCGAUAGGGUGAGGGGA-30.
The molecule is a variant of the previously published
Spiegelmer STAR-F12D43–48, whereby the adenosines at
positions 30 and 35 were substituted to uridines [22]. The
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biologically inactive control Spiegelmer has the arbitrary
sequence 50-UAAGGAAACUCGGUCUGAUGCGGUAGC
GCUGUGCAGAGCU-30. The Spiegelmer used in the
in-vivo studies (NOX-A42) was modified with a 40-kD
polyethylene glycol moiety to reduce renal excretion [21].
All Spiegelmers were synthesized at NOXXON Pharma AG
(Berlin, Germany).
Male adult Wistar rats (200–300g) were used for all
experiments. Rats had ad libitum access to standard
laboratory rat chow (890 25 W16, Provimi Kliba, Gossau,
Switzerland) and water, unless stated otherwise. The animals
were maintained in a temperature-controlled room on an
artificial 12 : 12-h dark–light cycle (21711C, lights on at
03.00h) and adapted to the housing conditions and handling
for at least 2 weeks before the start of the experiments.
The slice preparation of the subfornical organ and the
electrophysiological recording technique were identical to
the procedures described previously [9,17]. Briefly, extra-
cellular recordings of action potentials from spontaneously
active subfornical organ neurons were obtained using glass
coated platinum–iridium electrodes. After recording the
baseline activity of a single neuron for at least 5min,
stimulations were conducted by switching to a superfusion
solution (10ml) containing the investigated drugs. The
following stimuli were applied: (i) rat amylin (107M,
Bachem AG, Bubendorf, Switzerland), (ii) rat amylin
(107M) plus anti-amylin Spiegelmer (50 107M) and
(iii) rat amylin plus inactive Spiegelmer (50 107M). The
Spiegelmers were dissolved in distilled water and were
preincubated with amylin for 15min at room temperature
before the start of the superfusion. When amylin was
applied alone the amylin solution was kept under the same
conditions. To exclude that the Spiegelmers cause any
changes in the discharge rate, control superfusions of these
substances (50 107M) were applied without amylin.
Action potential recordings were analyzed using the soft-
ware Spike2 (Cambridge Electronic Design, England, UK).
From the continuously recorded rate meter counts, the
average discharge rate of each neuron was evaluated for 60 s
prior to the stimulus. This value (spontaneous discharge
rate) was used to normalize changes in firing rate, expressed
as % change of the spontaneous discharge rate. If the
averaged change of discharge rate during the amylin
response was larger than 720% and 70.5 spikes/s, the
neuron was considered amylin sensitive. In addition to the
mean change of the discharge rate during the entire
responses, the peak values of the responses were calculated
on a basis of a 30-s interval during which the firing rate was
maximal. Finally, the duration between the application of
the drugs and the onset of effect (latency) and the duration
of the entire responses were determined. The parameters
of the electrophysiological responses were expressed as
means7standard errors (M7SEM).
For the immunohistological c-Fos studies four groups of
rats (200–230 g) were used (n¼5 per group). All animals
were food deprived for 26 h beginning at dark onset. After
19 h of fasting, that is 5 h before subsequent dark onset, two
groups were pretreated with NOX-A42 (3mg/kg intrave-
nously into the tail vein), whereas the two other groups
received control infusions of saline. Ten minutes before dark
onset, one Spiegelmer and one saline treated group were
injected with amylin (20 mg/kg subcutaneously), whereas
the two remaining groups received saline. Two hours after
these treatments, rats were deeply anesthetized (pentobar-
bital 100mg/kg, intraperitoneally) and transcardially per-
fused with ice-cold sodium phosphate-buffered saline
(0.1M, pH 7.4), followed by 4% paraformaldehyde in
0.1M phosphate-buffered saline. The immunohistological
c-Fos staining was identical to the method described
previously [23].
In the electrophysiological studies, statistical differences
between the responses were evaluated by Friedman
Repeated Measures ANOVA on Ranks followed by Stu-
dent-Newman–Keuls method for multiple pairwise com-
parison. c-Fos immunoreactive (c-Fos-IR) cells were counted
for each animal from an average number of 24 slices of the
area postrema (according to the brain map of Paxinos and
Watson [24]). All slices from each animal were taken from
corresponding rostrocaudal levels to exclude quantitative
differences owing to variations in the cross-sectional area.
The data are expressed as average number of cells/
section7SEM. Differences between the groups were eval-
uated by one-way analysis of variance and the least
significant difference pair wise multiple comparison test.
For all statistical tests, Po0.05 was considered significant.
Results
Only amylin-sensitive subfornical organ neurons were
included in the electrophysiological analysis to test for the
blocking capacity of the anti-amylin Spiegelmer. In total, six
amylin responsive cells have been successfully tested with
all three stimuli (amylin, amylin/anti-amylin Spiegelmer
and amylin/inactive Spiegelmer). In contrast to the inactive
Spiegelmer, the anti-amylin Spiegelmer effectively blocked
the amylin-mediated excitations in the subfornical organ.
Figure 1a illustrates a typical recording of an amylin-
sensitive subfornical organ neuron demonstrating the
blockade of amylin’s excitatory action when coapplied with
anti-amylin Spiegelmer, whereas the inactive Spiegelmer
did not affect the amylin-induced response. The average
excitatory effect of amylin calculated from the mean
increases in firing rates of all tested neurons was signifi-
cantly higher than the averaged response observed after a
coapplication of amylin and the active Spiegelmer. The
mean excitatory response after application of amylin plus
inactive Spiegelmer was similar to that of amylin alone.
Table 1 summarizes all mean effect parameters for the
different stimuli. Neither the active Spiegelmer (n¼3) nor
the inactive Spiegelmer (n¼3) affected neuronal activity
when superfused alone (Fig. 1b).
In experimentally independent in-vivo studies we con-
firmed the amylin antagonistic action of the Spiegelmer
NOX-A42, which significantly attenuated the amylin-in-
duced activation of area postrema neurons as detected by c-
Fos expression. Almost no activated neurons were observed
in saline/saline-treated animals and in NOX-A42/saline-
treated rats (Fig. 2). Saline/amylin treatment led to
abundant c-Fos positive nuclei and significantly fewer cells
were detected in NOX-A42/amylin injected animals. In the
Spiegelmer pretreated group the amylin-induced c-Fos
response in the area postrema was decreased by 54%
relative to the saline/amylin-injected animals (Fig. 3).
Discussion
In line with previous studies [9,15], amylin significantly
stimulated subfornical organ and area postrema neurons
18 56 Vol 18 No 17 19 November 2007
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that are considered the main target structures for circulating
amylin. As shown by electrophysiological recordings,
coapplication of the inactive Spiegelmer did not affect
amylin’s excitatory responses on subfornical organ neurons.
The reason why the latency of the amylin-mediated
excitation was no longer under the blockade of amylin, as
it may be expected, is unknown. In fact, there rather
appeared to be a tendency for a shorter onset, which,
however, was not significant. Neither the active nor the
inactive control Spiegelmer seemed to produce any toxic or
unspecific side effects when superfused alone.
Various amylin receptor antagonists had been useful in
identifying amylinergic responses. AC187 is one of the most
potent amylin receptor blockers [18]. In this study we
introduced a member of a new class of L-RNA-based
hormone antagonists, the anti-amylin Spiegelmer NOX-
A42. In contrast to classic hormone antagonists, Spiegelmers
do not interact with the hormone receptor but reduce
hormone action by a direct binding and thus reduce the
biologically active circulating hormone. As Spiegelmers are
L-RNA compounds, they are not targets for nucleases that
metabolize D-oligonucleotides [19]. This leads to a tremen-
dous stability of Spiegelmers in biological fluids [19].
Table 1 E¡ect parameters of the electrophysiological responses of rat
subfornical organ neurons
E¡ect parameter Amylin Amylin+
inactive
Spiegelmer
Amylin+
anti-amylin
Spiegelmer
Mean latency (s) 74.5723.6a 84.3728.9a 36.3711.3a
Mean response (%) 45.475.8a 44.8711.9a 4.873.9b
Mean response (spikes/s) 3.470.4a 3.470.6a 0.470.2b
Peak response (spikes/s) 4.770.4a 4.771.0a 0.870.3b
Mean response duration (s) 1142.57211.5a 1171.27220.5a 381.2737.6b
Parameters are given for the responses induced by amylin (107M) when
superfused alone and in combination with inactive Spiegelmer or the anti-
amylin Spiegelmer (both 50107M). Anti-amylin Spiegelmer signi¢cantly
blocked the amylin-induced excitatory response compared with superfusion
of amylin alone or in combination with the inactive Spiegelmer.Di¡erent let-
ters indicate signi¢cant di¡erences (Po0.05).Values aremeans7SEM (n¼6).
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Fig.1 (a) Continuous ratemeter recording of a spontaneously active neuron from the rat subfornical organ.The amylin-induced excitation was antag-
onized by coapplication of the anti-amylin Spiegelmer, whereas the biologically inactive Spiegelmer did not a¡ect the amylin-mediated excitation.
(b) Continuous rate meter recording of a spontaneously active neuron from the rat subfornical organ. Neither the inactive Spiegelmer nor the anti-
amylin Spiegelmer a¡ected neuronal activity when superfused alone.
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Therefore, Spiegelmers are useful antagonists for experi-
mental purposes. The biostable anti-amylin Spiegelmer
NOX-A42 could be a promising new tool to chronically
block endogenous amylin action without using laborious
and more invasive techniques like osmotic minipumps for
chronic AC187 infusion. Under certain pathophysiological
conditions, excessive amylin release may contribute to
disorders in energy homeostasis, for example, cancer
anorexia occurring during certain pancreatic neoplastic
diseases that are associated with chronically supraphysio-
logical plasma amylin levels [25]. Amylin inhibition through
NOX-A42 could be a promising new approach for the
treatment of such disorders.
Conclusion
In summary, this study provides in-vitro and in-vivo
evidence that the anti-amylin Spiegelmer antagonizes
amylinergic responses on neuronal function in the brain.
Long acting anti-amylin Spiegelmers may not only
be useful as experimental tools but also as possible
therapeutic compounds for disorders characterized by
hyperamylinemia.
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